Intelence(etravirine)
Etravirine, Intelence (etravirine) is a small molecule pharmaceutical. Etravirine was first approved as Intelence on 2008-01-18. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Etravirine, Intelence (discontinued: Etravirine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Etravirine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INTELENCE | Johnson & Johnson | N-022187 RX | 2008-01-18 | 3 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| etravirine | ANDA | 2024-03-05 |
| intelence | New Drug Application | 2023-08-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
88 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 10 | 16 | 12 | 10 | 14 | 59 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 4 | 7 | 1 | 5 | 8 | 24 |
| Hiv | D006678 | — | — | 5 | 1 | 7 | 4 | 6 | 23 |
| Infections | D007239 | EFO_0000544 | — | 4 | 3 | 2 | 2 | 2 | 13 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | 5 | 1 | 1 | 3 | 9 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | 1 | 1 | 2 | 5 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 1 | — | 1 | 1 | 2 | 5 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | 1 | 1 | 2 | 4 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 1 | 1 | 1 | 3 |
| Communicable diseases | D003141 | — | — | — | 1 | — | 2 | — | 3 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv-2 | D015498 | — | — | — | 1 | — | — | 1 | 2 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | — | 1 | — | — | — | 1 |
| Ataxia | D001259 | — | R27.0 | — | 1 | — | — | — | 1 |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 1 | — | — | — | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | 1 | — | — | — | 1 |
| Coinfection | D060085 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | 1 | — | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Hiv seropositivity | D006679 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etravirine |
| INN | etravirine |
| Description | Etravirine is an aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directly to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral agent. It is a dinitrile, an organobromine compound, an aminopyrimidine and an aromatic ether. |
| Classification | Small molecule |
| Drug class | antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br |
Identifiers
| PDB | — |
| CAS-ID | 269055-15-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL308954 |
| ChEBI ID | 63589 |
| PubChem CID | 193962 |
| DrugBank | DB06414 |
| UNII ID | 0C50HW4FO1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Etravirine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,110 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,820 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use